$124.25
7.13[6.09%]
At close: Apr 24
$124.25
0[0.00%]
After Hours: 4:05PM EDT
Sarepta Therapeutics
(NASDAQ:SRPT)Latest News for Sarepta Therapeutics Stock (NASDAQ:SRPT)
Sarepta Therapeutics Stock (NASDAQ: SRPT)
Categories: All
Wednesday, April 24, 2024
Thursday, April 04, 2024
Friday, March 08, 2024
Friday, March 01, 2024
Thursday, February 29, 2024
- Cantor Fitzgerald Reiterates Neutral on Sarepta Therapeutics, Maintains $128 Price TargetBenzinga Newsdesk - Feb 29, 2024, 1:38PM
- Sarepta Therapeutics shares are trading lower after the company reported Q4 financial results. Needham maintained a Buy rating on the stock but lowered its price target from $169 to $166.Benzinga Newsdesk - Feb 29, 2024, 1:17PM
- RBC Capital Maintains Outperform on Sarepta Therapeutics, Raises Price Target to $157Benzinga Newsdesk - Feb 29, 2024, 12:49PM
- Citigroup Maintains Buy on Sarepta Therapeutics, Raises Price Target to $172Benzinga Newsdesk - Feb 29, 2024, 12:09PM
- Barclays Maintains Overweight on Sarepta Therapeutics, Raises Price Target to $185Benzinga Newsdesk - Feb 29, 2024, 8:31AM
- Needham Maintains Buy on Sarepta Therapeutics, Lowers Price Target to $166Benzinga Newsdesk - Feb 29, 2024, 7:53AM
Wednesday, February 28, 2024
- Sarepta Therapeutics shares are trading higher after the company reported better-than-expected Q4 financial results.Benzinga Newsdesk - Feb 28, 2024, 4:24PM
- Sarepta Therapeutics: Q4 Earnings InsightsBenzinga Insights - Feb 28, 2024, 4:15PM
- Sarepta Therapeutics Q4 2023 Adj EPS $0.82 Beats $0.01 Estimate, Sales $396.78M Beat $385.81M EstimateBenzinga Newsdesk - Feb 28, 2024, 4:13PM
- Earnings Scheduled For February 28, 2024Benzinga Insights - Feb 28, 2024, 6:24AM
Tuesday, February 27, 2024
Monday, February 26, 2024
Tuesday, February 20, 2024
Monday, February 19, 2024
Friday, February 16, 2024
- Needham Maintains Buy on Sarepta Therapeutics, Raises Price Target to $169Benzinga Newsdesk - Feb 16, 2024, 1:36PM
- FDA Fast-Tracks Review Of Sarepta's Groundbreaking Muscular Dystrophy Treatment With $1B Market In SightVandana Singh - Feb 16, 2024, 1:07PM
- Why DoorDash Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Friday's Mid-Day SessionAvi Kapoor - Feb 16, 2024, 1:04PM
- Applied Materials Posts Upbeat Earnings, Joins Texas Roadhouse, Vulcan Materials And Other Big Stocks Moving Higher On FridayAvi Kapoor - Feb 16, 2024, 10:09AM
- Sarepta Therapeutics shares are trading higher after the FDA accepted and filed the company's efficacy supplement to the Biologics License Application for ELEVIDYS.Benzinga Newsdesk - Feb 16, 2024, 8:23AM
- 12 Health Care Stocks Moving In Friday's Pre-Market SessionBenzinga Insights - Feb 16, 2024, 8:06AM
- Sarepta Therapeutics Reports FDA Acceptance Of An Efficacy Supplement To Expand ELEVIDYS Indication; Priority Review Granted, With Review Goal Date Of June 21, 2024Benzinga Newsdesk - Feb 16, 2024, 7:02AM
Thursday, February 15, 2024
Wednesday, February 14, 2024
Monday, February 12, 2024
Wednesday, January 31, 2024
Tuesday, January 30, 2024
Monday, January 29, 2024
- Needham Reiterates Buy on Sarepta Therapeutics, Maintains $140 Price TargetBenzinga Newsdesk - Jan 29, 2024, 1:11PM
- Sarepta Therapeutics' Next-Gen Duchenne Muscular Therapy Shows Efficacy At Less Frequent DosingVandana Singh - Jan 29, 2024, 11:48AM
- Sarepta Therapeutics Announces Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51Benzinga Newsdesk - Jan 29, 2024, 7:02AM
Thursday, January 25, 2024
Tuesday, January 16, 2024
Wednesday, January 10, 2024
Tuesday, January 09, 2024
- Stocks Flip To Losses, Nvidia Defies Gravity, Bitcoin Pauses For A Breather: What's Driving Markets Tuesday?Piero Cingari - Jan 9, 2024, 2:14PM
- Sarepta Expects Prelim Gene Therapy Revenue To Be $131M In Q4, $200M For Fiscal YearVandana Singh - Jan 9, 2024, 12:58PM
- Sarepta Therapeutics shares are trading higher after the company announced expected preliminary Q4 net product revenues.Benzinga Newsdesk - Jan 9, 2024, 12:21PM
- Acuity Brands Posts Upbeat Earnings, Joins Accolade, Urban Outfitters And Other Big Stocks Moving Higher On TuesdayAvi Kapoor - Jan 9, 2024, 10:59AM
- Wedbush Reiterates Outperform on Sarepta Therapeutics, Maintains $224 Price TargetBenzinga Newsdesk - Jan 9, 2024, 9:52AM
Monday, January 08, 2024
- Sarepta Therapeutics Reports Preliminary Q4 Net Product Revenue For ELEVIDYS Are Expected To Be ~$131.3M And $200.4M For FY23; Preliminary Total Net Product Revenue Is Expected To Total $1.145B For FY23Benzinga Newsdesk - Jan 8, 2024, 12:01PM
- 5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway MondayShanthi Rexaline - Jan 8, 2024, 6:04AM